| Abstract | Protein tyrosine kinases (PTKs) and their substrates are emerging as attractive therapeutic targets and potential biomarkers for molecular classifications, prediction of clinical outcome and monitoring response to cancer treatments. The exciting move toward kinase-targeted therapy has brought new technical challenges in profiling protein kinase genes and proteins as surrogate clinical biomarkers, particularly in light of clinical data correlating specific mutations in PTKs with either sensitivity or resistance to targeted therapy. This chapter discusses the impact of mutations on protein conformation, protein phosphorylation, and drug response and the utility of proteomic technology to mine the phosphoproteome for PTK profiling and prediction of response to targeted therapies. |
|---|
